Another influenza vaccine candidate, FLU-v, containing four short peptides targeting influenza conserved internal proteins M1, NPA, NPB, and M2 and adjuvanted by Montanide ISA-51 induces cross-reactive cell-mediated immunity and provides protection against mild-to-moderate influenza disease in human participants [42,43]. The gene discussed is NPB; the disease is influenza.